Clearside Biomedical is a biopharmaceutical company focused on revolutionizing treatment for sight-threatening back-of-the-eye diseases. IPO in June, 2016 (NASDAQ:CLSD).

Developer of an online platform for clinical payments. Acquired by BioClinica on January 19, 2016.

Curoverse developed a genomic and biomedical computing platform. Acquired by Veritas Genetics in August 2017.

G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. IPO in May 2017 (NASDAQ: GTHX) Acquired by Pharmacosmos in 2024

Graybug Vision, Inc. was a clinical-stage ophthalmology company developing sustained-release therapies. IPO in September 2020 (NASDAQ: GRAY).

Founded by pediatricians, developing medical content in an educational format embraced by children. Acquired by Falfurrias 2024

Developer of innovative neurodegeneration small-molecules intended to establish a platform for novel drug discovery.Acquired by Bial in October 2020.

Operator of a biopharmaceutical agency intended to offer drugs for the treatment of diabetes and other metabolic disorders.
